MM&M

Dyne Therapeutics’ Duchenne muscular dystrophy treatment shows promise

Dyne Therapeutics’ experimental treatment for Duchenne muscular dystrophy (DMD) showed promise in new data from a small Phase 1/2 trial dubbed DELIVER, the pharma announced this week. The drug, ...
The American Journal of Managed Care

DYNE-251 Granted FDA Breakthrough Therapy Designation for DMD

DYNE-251 received FDA breakthrough therapy designation for DMD, showing promising clinical evidence of improvement over existing therapies. The DELIVER trial demonstrated sustained functional ...
Nasdaq

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting

- Based on Type C meeting and new data, Dyne submitted revised ACHIEVE trial protocol to FDA elevating vHOT to primary endpoint for U.S. Accelerated Approval - - New positive clinical data from Phase ...
zacks

Dyne Therapeutics Stock Gains 4.5% After BLA Filing for DMD Therapy

Dyne Therapeutics submitted a BLA to the FDA for z-rostudirsen in DMD patients amenable to exon 51 skipping. Dyne Therapeutics' BLA filing is backed by phase I/II data showing improved dystrophin and ...
Nasdaq

Dyne Therapeutics Announces First Patient Dosed in Phase 1/2 DELIVER Clinical Trial of DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for ...